Continuity in Cancer Care®: Aligning Primary and Oncology Specialty Care to Improve Long-Term Management of Multiple Myeloma Patients

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Internet - based

Activity Overview

Multidisciplinary care is a crucial element of supporting patients throughout the continuum of care for multiple myeloma (MM) as new treatment options improve progression-free and overall survival. Multidisciplinary care teams need to work cohesively to optimize clinical outcomes in areas such as bone health, mobility, safety, sexual dysfunction, kidney disease management, social and psychological health, and pain management.

Understanding the possible implications of constantly emerging clinical data in MM, both in the newly diagnosed setting and the relapsed/refractory setting, is important to the appropriate management of patients with MM. It is crucial to effectively manage potential adverse events associated with therapy, including thromboembolic risk (elevated in patients with MM) and treatment-related cardiotoxicity. Strategies for managing other adverse events, such as peripheral neuropathy, gastrointestinal toxicity, pulmonary toxicity, cutaneous reactions, tumor lysis syndrome, and hepatotoxicity must also be considered during the treatment planning process.

To help you meet this challenge, this Continuity in Cancer Care^® will feature case presentations given by prominent experts in the field to discuss strategies that support the continuity of care for patients with MM. The latest data in the management of treatment- and nontreatment-related toxicities with comorbid conditions will be discussed as well as the implications for clinical practice.

Benefits of Participating

• Utilize the panel discussion amongst primary care physicians (PCPs) and medical oncologists who specialize in MM as insight to provide best practice, personalized care for patients
• Promote strategies for routine communication with PCPs to support continuity of care
• Achieve increased application of current clinical data to manage treatment- and nontreatment-related toxicities
• Manage comorbidities as a multidisciplinary team between oncology and primary care
• Apply the presented challenging clinical cases to daily practice during screening and treatment of patients with possible or confirmed MM

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen Inc and Celgene Corporation.

Target Audience

This educational activity is directed toward medical oncologists and primary care physicians who treat or manage patients with myeloma. Nurse practitioners, physicians’ assistants, nurses, pharmacists, and other healthcare professionals interested in the treatment of myeloma are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Determine disease- and treatment-related toxicities among patients with myeloma in the context of common underlying comorbidities among patients with these tumors.
• Explain clinical trial evidence that informs decision making to individualize management approaches based on patient comorbidities in myeloma treatment settings.
• Apply individualized care approaches based on trial evidence that optimizes outcomes and integrates patient risk for short and long-term treatment-related comorbidity.
• Identify methods to coordinate care between the medical oncologist and primary care practitioners to optimize outcomes and mitigate risk among patients with myeloma.

Faculty, Staff, and Planners’ Disclosures

Faculty

Sagar Lonial, MD, FACP
Professor and Department Chair
Department of Hematology and Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Celgene, Janssen, Takeda; Consultant: Celgene, Novartis, Bristol-Myers Squibb, Takeda, Janssen, GlaxoSmithKline, Amgen, AbbVie.

Ajai Chari, MD
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director Clinical Research, Multiple Myeloma Program
Associate Director, Mount Sinai Cancer Clinical Trials Office
New York, NY

Disclosures: Grant/Research Support: Amgen, Array Biopharma, Celgene, GlaxoSmithKlein, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, Seattle Genetics; Consultant: Amgen, Bristol-Myers Squibb, Celgene, Millennium/Takeda, Janssen, Karyopharm; Other: Scientific Advisory Boards: Amgen, Celgene, Millennium/Takeda, Janssen, Karyopharm, Sanofi, Seattle Genetics.

Jennifer Zreloff, MD
Assistant Professor of Internal Medicine
Emory University School of Medicine
Atlanta, GA

Disclosures: no relevant financial relationships with commercial interests to disclose.

Priscilla A. Bresler, MD
Assistant Professor of General Internal Medicine and Oncological Sciences
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.